相关实验视频

Updated: Jun 24, 2025

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

重编程外体,用于免疫重塑光动力疗法,对抗非小细胞肺癌

Jiao Guo¹, Wei Zhao¹, Xinyu Xiao¹

¹School of Basic Medical Science, Chongqing Medical University, Chongqing, 400016, China.

Bioactive materials

|June 3, 2024

概括

一个结合光动力学疗法和免疫疗法的新型纳米平台显示出治疗非小细胞肺癌 (NSCLC) 的前景. 这种方法针对瘤,提高氧气水平,并重新编程免疫微环境,以改善治疗结果.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
癌症治疗癌症治疗

背景情况:

晚期非小细胞肺癌 (NSCLC) 具有重大治疗挑战,患病率和死亡率高.
目前的治疗方法往往是侵入性的,缺乏足够的临床有效性.
迫切需要创新的治疗策略,以减少侵入性和提高疗效.

研究的目的:

开发一种用于NSCLC的协同光动力学疗法 (PDT) 和免疫疗法的新型纳米平台.
克服现有组合疗法的局限性,包括药物输送不良和免疫抑制瘤微环境 (TME).
创建一个有针对性的传递系统,调节TME以增强抗癌免疫反应.

主要方法:

构建一个纳米平台 (ICG@MnO2@Exo-anti-PD-L1),将绿色 (ICG) 和二氧化 (MnO2) 封装在与抗PD-L1抗体装饰的外体内.
针对性地将纳米平台传递给PD-L1表达NSCLC细胞.
在现场通过MnO2产生氧气以缓解瘤缺氧和使用近红外 (NIR) 辐射激活PDT.
通过释放抗PD-L1来调节TME,以增强T细胞的反应,并使巨细胞从M2变为M1表型.

主要成果:

该纳米平台实现了精确的输送到瘤部位,并在酸性TME中控制释放抗PD-L1.
MnO2有效地将过氧化转化为氧气,缓解瘤缺氧.
在NIR照射下,ICG产生单点氧,导致瘤细胞死亡.
该疗法成功地重塑了免疫微环境,促进了抗瘤免疫力.

结论:

开发的ICG@MnO2@Exo-anti-PD-L1纳米平台为NSCLC提供了一个有前途的多模式治疗策略.
这种方法有效地结合了PDT和免疫疗法,通过精确准瘤和调节TME.
该纳米平台展示了克服当前治疗局限性的潜力,并改善了晚期NSCLC患者的治疗结果.

关键词:

免疫治疗是一种免疫疗法.非小细胞肺癌是非小细胞肺癌.在PD-L1中.在PDT中使用PDT.有针对性的交付目标.瘤微环境是一个微环境.

更多相关视频

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Somatic to iPS Cell Reprogramming

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...